Ann: Investor update, page-5

That was a good juicy update ... wedge will break soon - it loves that high....

Still probably more likely on base once stock is allocated

but who knows tricky position, wedge says sooner and too late once allocated.



Patrys’ lead asset PAT-DX1 exploits the DNA Damage Response (DDR) mechanism to block DNA repair and preferentially kill cancer cells. In animal models, PAT-DX1 has shown efficacy in killing cancer cells with a range of DDR gene mutations such as BRCA2 and PTEN – and importantly it does not kill cells without those mutations (i.e. healthy cells). This could be a game changer in the oncology space. PAT-DX1 is the only known antibody to have shown efficacy as a single agent via the synthetic lethality model. Unlike other antibodies and 98% of small molecules, it can also cross the blood brain barrier (BBB), which provides all-important access to cancer cells in the central nervous system.

Synthetic lethality has also attracted a lot of deal making attention in the past few weeks. In May 2020, Bristol Myers Squibb closed a US$65M deal with Repare Therapeutics for access to its DDR technology platform, and Glaxo Smith Kline inked a deal with IDEAYA Biosciences for three discovery-stage synthetic lethality assets (US$100M upfront, US$20M equity investment, potential development and regulatory milestone payments of around US$465-485M and commercial milestones of US$475M for two of the more advanced programs). It is clear that big pharma and big biotech are increasingly compelled by the elegance of synthetic lethality and DDR therapeutic approaches for treating a range of tumours.

Patrys is in the enviable position of developing a novel therapeutic that combines the established safety and toxicology advantages of antibody therapeutics with the power of synthetic lethality – and it is designed to ‘topple’ the most stubborn, hard-to-reach cancers.